A dose-ranging study of the effects of mequitazine on actual driving, memory and psychomotor performance as compared to dexchlorpheniramine, cetirizine and placebo

Clinical and Experimental Allergy

Volumn 34, Issue 2, 2004, Pages 250-258

  Theunissen, E L ^a   Vermeeren, A ^a   Van Oers, A C M ^a   Van Maris, I ^a   Ramaekers, J G ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Antihistamines; Attention; Cetirizine; Dexchlorpheniramine; Driving; H 1 receptor antagonist; Memory; Mequitazine; Psychomotor performance; Sedation

Indexed keywords

CETIRIZINE; DEXCHLORPHENIRAMINE; MEQUITAZINE; PLACEBO;

ARTICLE; COGNITION; CONTROLLED STUDY; DOSE RESPONSE; DRIVING ABILITY; DRUG EFFECT; DRUG MEGADOSE; HUMAN; MEDICAL ASSESSMENT; MEMORY; PRIORITY JOURNAL; PSYCHOMETRY; PSYCHOMOTOR PERFORMANCE; QUESTIONNAIRE; STANDARD; STATISTICAL ANALYSIS;

ADULT; AUTOMOBILE DRIVING; CETIRIZINE; CHLORPHENIRAMINE; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; PHENOTHIAZINES; PSYCHOMETRICS; PSYCHOMOTOR PERFORMANCE; STATISTICS, NONPARAMETRIC;

EID: 1542315413     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2004.01874.x     Document Type: Article

References (60)

1. Panula P, Karlstedt K, Sallmen T et al. The histaminergic system in the brain: structural characteristics and changes in hibernation. J Chem Neuroanat 2000; 18:65-74.
2. Steinbusch HW. Distribution of histaminergic neurons and fibers in rat brain. Comparison with noradrenergic and serotonergic innervation of the vestibular system. Acta Otolaryngol 1991; 479 (Suppl.):12-23.
3. Onodera K, Yamatodani A, Watanabe T, Wada H. Neuropharmacology of the histaminergic neuron system in the brain and its relationship with behavioral disorders. Prog Neurobiol 1994; 42:685-702.
4. Yamatodani A, Inagaki N, Panula P, Itowi N, Watanabe T, Wada H. Structure and functions of the histaminergic neurone system. In: Born GVR, ed. Handbook of experimental pharmacology. Berlin: Springer-Verlag, 1991; 243-83.
5. Onoe H, Yamatodani A, Watanabe T et al. Prostaglandin E2 and histamine in the posterior hypothalamus. J Sleep Res 1992; 1 (Suppl. 1):166.
6. Passalacqua G, Bousquet J, Bachert C et al. The clinical safety of H1-receptor antagonists An EAACI position paper. Allergy 1996; 51:666-75.
7. Snyder SH, Snowman AM. Receptor effects of cetirizine. Ann Allergy 1987; 59 (6 Part 2):4-8.
8. Rombaut NEI, Hindmarch I. Psychometric aspects of antihistamines: a review. Hum Psychopharmacol 1994; 9:157-69.
9. O'Hanlon JF, Ramaekers JG. Antihistamine effects on actual driving performance in a standard test: a summary of Dutch experience, 1989-94. Allergy 1995; 50:234-42.
10. Kay GG. The effects of antihistamines on cognition and performance. J Allergy Clin Immunol 2000; 105 (6 Part 2):S622-7.
11. Blamoutier J. Comparative trial of two antihistamines, mequitazine and brompheniramine. Curr Med Res Opin 1978; 5:366-70.
12. Gervais P, Gervais A, De Beule R, Van der Bijl W. Essai compare d'un nouvel antihistaminique, la mequitazine, et d'un placebo. Acta Allergol 1975; 30:286-97.
13. Van Wauwe J, Awouters F, Neimegeers CJ, Janssens F, Van Nueten JM, Janssen PA. In vivo pharmacology of astemizole, a new type of H1-antihistaminic compound. Arch Int Pharmacodyn Ther 1981; 251:39-51.
14. Muler H, Blum F. Essai compare de deux antihistaminiques: mequitazine et dexchlorpheniramine. Ann Otolaryngol Chir Cervicofac 1978; 95:433-9.
15. Woodward JK, Munro NL. Terfenadine, the first non-sedating antihistamine. Arzneimittelforschung 1982; 32:1154-6.
16. Hindmarch I, Easton JC. A placebo-controlled assessment of mequitazine and astemizole in tests of psychomotor ability. Int J Clin Pharmacol Res 1986; 6:457-64.
17. Shamsi Z, Hindmarch I. Sedation and antihistamines: a review of inter-drug differences using proportional impairment ratios. Hum Psychopharmacol Clin Exp 2000; 15 (Suppl. 1):S3-30.
18. Yanai K, Okamura N, Tagawa M, Itoh M, Watanabe T. New findings in pharmacological effects induced by antihistamines: from PET studies to knock-out mice. Clin Exp Allergy 1999; 29 (Suppl. 3):29-36.
19. Beaumont D, Hugonot L, Hugonot R. Etude comparative de la terfénadine et de la méquitazine dans le traitement symptomatique de la rhinite allergique pollinique. Tempo Méd 1986; 224:53-9.
20. Caille EJ. Etude comparative en double aveugle de la méquitazine, de la dexchlorphéniramine et d'un placebo sur la vigilance. Gazette Méd France 1979; 86:3737-44.
21. Rimmer SJ, Church MK. The pharmacology and mechanisms of action of histamine H1-antagonists. Clin Exp Allergy 1990; 20 (Suppl. 2):3-17.
22. Wood SG, John BA, Chasseaud LF, Yeh J, Chung M. The metabolism and pharmacokinetics of 14C-cetirizine in humans. Ann Allergy 1987; 59 (6 Part 2):31-4.
23. CVZ. Farmacotherapeutisch Kompas. Amstelveen: College Voor Zorgverzekering, 1999.
24. Ylitalo P, Nieminen K, Wilen-Rosenqvist G et al. Serum levels and urinary excretion of mequitazine after a single oral dose. Int J Clin Pharmacol Res 1989; 9:305-8.
25. O'Hanlon JF, Haak TW, Blaauw GJ, Riemersma JB. Diazepam impairs lateral position control in highway driving. Science 1982; 217:79-81.
26. Ramaekers JG, Uiterwijk MM, O'Hanlon JF. Effects of loratadine and cetirizine on actual driving and psychometric test performance, and EEG during driving. Eur J Clin Pharmacol 1992; 42:363-9.
27. Vuurman EF, Muntjewerff ND, Uiterwijk MM et al. Effects of mefloquine alone and with alcohol on psychomotor and driving performance. Eur J Clin Pharmacol 1996; 50:475-82.
28. Brookhuis KA, De Vries G, De Waard D. Acute and subchronic effects of the H1-histamine receptor antagonist ebastine in 10, 20 and 30 mg dose, and triprolidine 10 mg on car driving performance. Br J Clin Pharmacol 1993; 36:67-70.
29. Ramaekers JG, O'Hanlon JF. Acrivastine, terfenadine and diphenhydramine effects on driving performance as a function of dose and time after dosing. Eur J Clin Pharmacol 1994; 47:261-6.
30. Ramaekers G, Lamers J, Verhey F et al. A comparative study of the effects of carbamazepine and the NMDA receptor antagonist remacemide on road tracking and car-following performance in actual traffic. Psychopharmacology (Berl) 2002; 159:203-10.
31. Rey A. L'examen clinique en psychologie. Paris: Presses Universitaires de France, 1964.
32. Jex HR, McDonnell JD, Phatak AV. A 'critical' tracking task for man-machine research related to the operator's effective delay time. I. Theory and experiments with a first-order divergent controlled element. NASA CR-616, NASA Contract Rep NASA CR 1966: 1-105.
33. Moskowitz H. Laboratory studies of the effects of alcohol on some variables related to driving. J Safety Res 1973; 5:185-92.
34. Baddeley AD. A 3 min reasoning test based on grammatical transformation. Psychon Sci 1968; 10:341-2.
35. Curran S. Critical flicker fusion techniques in psychopharmacology. In: Hindmarch I, Stonier PD, eds. Human psychopharmacology. Chichester: Wiley, 1990; 21-38.
36. Schmitt JA, Riedel WJ, Vuurman EF, Kruizinga M, Ramaekers JG. Modulation of the critical flicker fusion effects of serotonin reuptake inhibitors by concomitant pupillary changes. Psychopharmacology (Berl) 2002; 160:381-6.
37. Sokolski KN, Nguyen BD, DeMet EM. Decreases in dilated pupil size in depressed patients with age may reflect adrenergic changes. Psychiatry Res 2000; 94:267-72.
38. Smith JM, Misiak H. Critical nicker frequency (CFF) and psychotropic drugs in normal human subjects - a review. Psychopharmacologia 1976; 47:175-82.
39. Mulder-Hajonides van der Meulen WREH. Measurement of subjective sleep quality. Proceedings of the International European Sleep Congress. Amsterdam: Elsevier, 1981.
40. Bond A, Lader M. The use of analogue scales in rating subjective feelings. Br J Med Psychol 1974; 47:211-8.
41. Nicholson AN, Stone BM. The H1-antagonist mequitazine: studies on performance and visual function. Eur J Clin Pharmacol 1983; 25:563-6.
42. Curran HV, Pooviboonsuk P, Dalton JA, Lader MH. Differentiating the effects of centrally acting drugs on arousal and memory: an event-related potential study of scopolamine, lorazepam and diphenhydramine. Psychopharmacology 1998; 135:27-36.
43. Vuurman EF, Uiterwijk MM, Rosenzweig P, O'Hanlon JF. Effects of mizolastine and clemastine on actual driving and psychomotor performance in healthy volunteers. Eur J Clin Pharmacol 1994; 47:253-9.
44. Robbe HWJ, O' Hanlon JF. Effects of acrivastine, acrivastine plus pseudoephedrine and triprolidine on highway driving. Maastricht: Institute for Drugs, Safety and Behavior University of Limburg, 1990.
45. Riedel WJ, Ramaekers G, Uiterwijk MM, O' Hanlon JF. Higher doses of terfenadine and loratadine: acute and subchronic effects on psychomotor and actual driving performance. Maastricht: Institute for Drugs, Safety and Behavior, University of Limburg, 1990, IGVG 90-12.
46. Louwerens JW, Gloerich ABM, de Vries G, Brookhuis KA, O'Hanlon JF. The relationship between drivers' blood alcohol concentration (BAC) and actual driving performance during high speed travel. In: Noordzij PC, Roszbach R, eds. Alcohol, drugs and traffic safety-T86. Amsterdam: Elsevier, 1987.
47. Borkenstein RF, Crowther RF, Shumate RP, Ziel WB, Zylman R. The role of the drinking driver in traffic accidents. Blutalkohol 1974; 11 (Suppl. 1):1-131.
48. Riedel WJ, Schoenmakers EAJM, O'Hanlon JF. Sedation and performance impairment with antihistamines. In: Kalinger MA, ed. Management of allergy in the 1990s. Toronto: Hans Huber, 1989; 38-49.
49. Mann RD, Pearce GL, Dunn N, Shakir S. Sedation with 'non-sedating' antihistamines: four prescription-event monitoring studies in general practice. Br Med J 2000; 320:1184-6.
50. Meltzer EO, Weiler JM, Widlitz MD. Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. J Allergy Clin Immunol 1996; 97:617-26.
51. Monroe EW. Chronic urticaria: review of nonsedating H1 antihistamines in treatment. J Am Acad Dermatol 1988; 19 (5 Part 1):842-9.
52. Nicholson AN, Turner C. Central effects of the H1-antihistamine, cetirizine. Aviat Space Environ Med 1998; 69:166-71.
53. Gengo FM, Gabos C, Mechtler L. Quantitative effects of cetirizine and diphenhydramine on mental performance measured using an automobile driving simulator. Ann Allergy 1990; 64:520-6.
54. Hindmarch I, Johnson S, Meadows R, Kirkpatrick T, Shamsi Z. The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and weal and flare. Curr Med Res Opin 2001; 17:241-55.
55. Volkerts ER, Van Willigenburg AP, Van Laar MW, Maes RA. Does cetirizine belong to the new generation of antihistamines? An investigation into its acute and subchronic effects on highway driving, psychometric test performance and daytime sleepiness. Hum Psychopharmacol Clin Exp 1992; 7:227-38.
56. Vermeeren A, Riedel WJ, van Boxtel MP, Darwish M, Paty I, Patat A. Differential residual effects of zaleplon and zopiclone on actual driving: a comparison with a low dose of alcohol. Sleep 2002; 25:224-31.
57. Sannita WG, Crimi E, Riela S, Rosadini G, Brusasco V. Cutaneous antihistaminic action of cetirizine and dose-related EEG concomitants of sedation in man. Eur J Pharmacol 1996; 300:33-41.
58. Shall L, Barkley A, Millard LG. H1 receptor antagonism of terfenadine, cetirizine and loratadine of histamine induced wheals in man. In: XIVth Congress of the European Academy of Allergology and Clinical Immunology, Berlin, 1989.
59. Urien S, Tillement JP, Ganem B, Kuch MD. A pharmacokinetic- pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine. Int J Clin Pharmacol Ther 1999; 37:499-502.
60. Ramaekers JG. Antidepressants and driver impairment: empirical evidence from a standard on-the-road test. J Clin Psychiatry 2003; 64:20-9.